Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses the side effects of novel drugs in chronic lymphocytic leukemia (CLL). According to Dr Ghia, the toxicity profile of novel drugs is better compared to immunochemotherapy but neverthless, side effects are to be expected. Therefore, the rules to start treatment remain the same, i.e. the disease has to be progressive. In order to manage patient expectations about receiving novel drugs, it is important to inform patients about these side effects as Dr Ghia explains.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Advertisement